Roche Holding AG pointed toward rising sales this year as its new cancer immune therapy Tecentriq gains wider use for lung tumors. Revenue will probably rise by a low to mid-single digit percentage at constant exchange rates, the same pace as earnings per share excluding some items, the Basel, Switzerland-based company said in a statement Wednesday.